



REVIEW

Distinct roles of *GRIN2A* and *GRIN2B* variants in neurological conditions

[version 1; peer review: 2 approved]

Scott J Myers ^{1,2}, Hongjie Yuan ^{1,2}, Jing-Qiong Kang³,
Francis Chee Kuan Tan ⁴, Stephen F Traynelis^{1,2}, Chian-Ming Low ^{4,5}

¹Center for Functional Evaluation of Rare Variants (CFERV), Emory University, Atlanta, GA, USA²Department of Pharmacology and Chemical Biology, Emory University, Atlanta, GA, USA³Department of Neurology, Vanderbilt Brain Institute, Vanderbilt Kennedy Center of Human Development, Vanderbilt University, Nashville, TN, USA⁴Department of Anaesthesia, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore⁵Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

V1 First published: 20 Nov 2019, 8(F1000 Faculty Rev):1940
<https://doi.org/10.12688/f1000research.18949.1>

Latest published: 20 Nov 2019, 8(F1000 Faculty Rev):1940
<https://doi.org/10.12688/f1000research.18949.1>

Abstract

Rapid advances in sequencing technology have led to an explosive increase in the number of genetic variants identified in patients with neurological disease and have also enabled the assembly of a robust database of variants in healthy individuals. A surprising number of variants in the *GRIN* genes that encode *N*-methyl-D-aspartate (NMDA) glutamatergic receptor subunits have been found in patients with various neuropsychiatric disorders, including autism spectrum disorders, epilepsy, intellectual disability, attention-deficit/hyperactivity disorder, and schizophrenia. This review compares and contrasts the available information describing the clinical and functional consequences of genetic variations in *GRIN2A* and *GRIN2B*. Comparison of clinical phenotypes shows that *GRIN2A* variants are commonly associated with an epileptic phenotype but that *GRIN2B* variants are commonly found in patients with neurodevelopmental disorders. These observations emphasize the distinct roles that the gene products serve in circuit function and suggest that functional analysis of *GRIN2A* and *GRIN2B* variation may provide insight into the molecular mechanisms, which will allow more accurate subclassification of clinical phenotypes. Furthermore, characterization of the pharmacological properties of variant receptors could provide the first opportunity for translational therapeutic strategies for these *GRIN*-related neurological and psychiatric disorders.

Keywords

NMDA receptors, *GRIN2A*, *GRIN2B*, GluN2A, GluN2B, mutations, neurological disorder, psychiatric disorders, autism, epilepsy, intellectual disability, ADHD, schizophrenia, precision medicine

Open Peer Review

Approval Status

	1	2
version 1 20 Nov 2019		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **David A. Lynch**, Children's Hospital of Philadelphia, Philadelphia, USA
2. **Wen-Jun Gao**, Drexel University College of Medicine, Philadelphia, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Chian-Ming Low (phclowcm@nus.edu.sg)

Author roles: **Myers SJ:** Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Yuan H:** Conceptualization, Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Kang JQ:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Tan FCK:** Writing – Original Draft Preparation, Writing – Review & Editing; **Traynelis SF:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Low CM:** Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: SFT is PI on a research grant from Allergan and Janssen and Emory University School of Medicine, is a member of the SAB for Sage Therapeutics, is co-founder of NeurOp Inc, and receives royalties for software. SFT and SJM are co-inventors on Emory-owned Intellectual Property that includes allosteric modulators of NMDAR function.

Grant information: HY was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health (NIH) under award number R01HD08237. SFT was supported by the National Institute of Neurological Disorders and Stroke (NINDS) of the NIH under award numbers NIH-NINDS R01NS036654 and R24NS092989 and R35NS111619. C-ML was supported by National University of Singapore grant R184000261101.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Myers SJ *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Myers SJ, Yuan H, Kang JQ *et al.* **Distinct roles of *GRIN2A* and *GRIN2B* variants in neurological conditions [version 1; peer review: 2 approved]** F1000Research 2019, 8(F1000 Faculty Rev):1940 <https://doi.org/10.12688/f1000research.18949.1>

First published: 20 Nov 2019, 8(F1000 Faculty Rev):1940 <https://doi.org/10.12688/f1000research.18949.1>

Introduction

Ionotropic glutamate receptors are ligand-gated ion channels that mediate excitatory synaptic transmission throughout the central nervous system. These receptors can be classified into at least three distinct families, and nomenclature is based on the initial discovery of selective activating agonists AMPA, kainate, and *N*-methyl-D-aspartate (NMDA) for their corresponding receptors, which arise from *GRIA*, *GRIK*, and *GRIN* genes, respectively. The *GRIN* gene family encodes three classes of NMDA receptor (NMDAR) subunits: the glycine-binding GluN1 (product of *GRIN1*), glutamate-binding GluN2 (*GRIN2A*, *GRIN2B*, *GRIN2C*, and *GRIN2D*), and the enigmatic glycine-binding GluN3 (*GRIN3A* and *GRIN3B*), the role of which remains poorly understood^{1,2}. Most NMDARs are tetrameric assemblies of two GluN1 and two GluN2 subunits. In terms of the evolutionary history of the NMDAR, it appears that four GluN2 paralogs (GluN2A–D) were produced by two rounds of gene duplication in a common vertebrate ancestor; the rounds diverged during early vertebrate evolution principally at their carboxyl-terminal domain (CTD)³. The first round of duplication gave rise to two GluN2 genes (the ancestors of GluN2A/B and GluN2C/D), and the second round gave rise to the four extant paralogs⁴. Having a common ancestry, GluN2A and GluN2B molecular structure and function should be similar, except for the divergent CTDs. However, there are strong differences between these two subunits on almost every level, including in how clinically relevant missense variants impact the receptor and patient. In this review, we will focus on the molecular and functional basis as to why GluN2A and GluN2B show strikingly different effects when missense mutations arise (for example, *de novo* in key gating motifs and different neurological disorders).

Glutamate receptor structure and function

All NMDAR subunits contain four semi-autonomous domains: an amino-terminal domain (ATD), agonist-binding domain (ABD), transmembrane domain (TMD), and CTD (Figure 1). The bilobed ABD of GluN2 binds L-glutamate within a cleft between two rigid lobes, S1 and S2, which form a clamshell-like structure that undergoes pronounced conformational changes upon ligand binding. The S1 lobe of the ABD, which resides distal to the ion channel, forms an interface between the ABD of adjacent subunits, allowing them to act as dimers⁵. For NMDARs, one GluN1 and one GluN2 ABD form a dimer, two of which exist within each tetrameric receptor⁶. The S2 lobe that is proximal to the channel contains primarily the polypeptide chain that connects the two transmembrane helices (M1 and M3) through flexible linkers and a two-turn helix (the pre-M1 helix) that lies parallel to the plane of the membrane. The S2 lobe undergoes considerable movement as the agonist binds to “close the clamshell” within the ABD of each subunit, which is the initial conformational change of several that ultimately lead to opening of the ion channel pore⁷. This combination of agonist binding and clamshell closure provides the energy to drive channel opening in all ionotropic glutamate receptors^{6,8–11}.

Most information on NMDAR location and function exists for diheteromeric receptors that are a tetrameric assembly of two GluN1 subunits and two identical GluN2 subunits^{1,2}. NMDARs are maximally activated when glycine binds to the ABD of GluN1 and L-glutamate binds to the ABD of GluN2¹. Three transmembrane helices (M1, M3, and M4) form the pore and are directly coupled to the ABD in all glutamate receptor subunits, and the pore is lined by a re-entrant loop (referred to as M2)^{12,13}




Figure 1. Domains of *N*-methyl-D-aspartate (NMDA) receptors. The crystal structure for GluN1/GluN2B receptors is shown in the left panel¹³ depicting the amino-terminal domain (ATD), the agonist-binding domain (ABD), and the transmembrane domain (TMD). Not shown is the intracellular carboxyl-terminal domain (CTD). The right panel displays a schematic of a *GRIN* subunit, and the subdomains and the clamshell features of the ATD and ABD are indicated.

that controls ion permeation and block¹⁴. Not surprisingly, single amino acid variants in these transmembrane helices, in the linkers that couple transmembrane helices to the ABD, and in the pore-lining re-entrant M2 loop can affect gating, ion permeation, and block^{15–21}. Part of the activation gate—the structure that occludes the flux of ions in the closed state—involves the M3 segment, including a highly conserved motif (SYTANLAAF)¹⁰. The process of opening and closing is highly dependent on these nine residues, residues in the pre-M1 region and a region preceding the fourth TMD^{1,6,22–24}.

The NMDAR is permeable to Ca²⁺ in addition to Na⁺ and K⁺^{14,22,25–27}, and the intraneuronal Ca²⁺ entry subsequent to NMDAR activation can engage intracellular signaling systems that lead to changes in gene expression²⁸, changes in post-translational modifications²⁹, and ultimately changes in synaptic strength³⁰. Once the pore opens, extracellular Mg²⁺ can join the traffic of ions moving through the channel to reach a deep binding site in the pore, the occupancy of which establishes channel block in a voltage-dependent manner (reviewed in 14). This endows the receptor with the ability to detect neuronal activity (in the form of depolarization) and simultaneous synaptic activity (in the form of release of glutamate). This coincidence detector is a central feature enabling NMDARs to participate in some, but not all, forms of synaptic plasticity³¹. Some NMDARs can undergo desensitization during persistent activation³², and the time course of desensitization for NMDARs is much slower than that for AMPA receptors¹. Both speed and extent of desensitization are subunit-dependent^{33,34}, providing further separation of temporal signaling properties that depend on the frequency of synaptic input³⁵.

There are profound differences in the properties of NMDARs that contain GluN2A compared with GluN2B. For example, the open probability with GluN2A is higher than with GluN2B^{35,36}. In addition, glutamate and glycine are both less potent at GluN2A compared with GluN2B³⁷ and thus GluN2A-containing NMDARs show a faster deactivation time course following removal of glutamate than GluN2B-containing NMDARs³⁸. The deactivation time course following glutamate removal sets the duration of the synaptic current³⁹ and thus GluN2A NMDARs will produce a faster synaptic current in comparison with GluN2B. GluN2A-containing receptors also desensitize more rapidly than GluN2B-containing receptors, which show a much slower desensitization time course³⁵. These two receptors show different sensitivity to extracellular negative allosteric modulators such as Zn²⁺^{40,41}, and the Zn²⁺ binding site in the ATD shows much higher potency for GluN2A than GluN2B⁴². These functional properties, as well as the intracellular CTD that controls receptor targeting to different regions of the plasma membrane, will enable a variety of distinct functions for GluN2A- and GluN2B-containing NMDARs in neurons. There is strong evidence for perisynaptic NMDARs which could play a range of different roles^{43,44}. Some evidence suggests that GluN2A preferentially distributes to the postsynaptic density, compared with GluN2B, which also distributes throughout the dendrite at extrasynaptic sites⁴⁵. This distinct localization has also been suggested to influence the participation of these two

receptor subunits in different forms of synaptic plasticity^{46–48}. Moreover, there are distinct roles of NMDARs of different subunit composition in neuroprotective signaling and cell death signaling that reflect both their localization and ability to pass current and Ca²⁺^{49–52}. However, the subcellular distributions of GluN2A and GluN2B are not absolute, and both subunits can be found both synaptically and extrasynaptically.

Developmental expression profile of GluN2A and GluN2B

The temporal expression profile of different NMDAR subunits is precisely controlled to coincide with critical periods in the development of different brain structures^{53–58}. Indeed, *GRIN2* gene expression in the brain changes throughout the postnatal developmental stages⁵⁹. The GluN2B subunit is highly expressed in the prenatal stages and its expression drops at the postnatal stages, becoming focally expressed in the forebrain. However, GluN2A is expressed at apparently low levels in the prenatal stages and increases upon birth^{53,60}. In rodents, *GRIN2A* mRNA appears detectable by *in situ* hybridization studies around postnatal day 6. There is a progressive developmental change from predominantly GluN1/GluN2B receptors to GluN1/GluN2A receptors in many brain regions^{58,61–63}, including thalamic and cortical neurons during the early postnatal development⁶⁴. The decrease in GluN2B-containing NMDARs at synapses is corroborated with the detection of shorter excitatory postsynaptic currents and a decrease in sensitivity to a specific GluN1/GluN2B receptor antagonist, ifenprodil^{65,66}. The prenatal expression of *GRIN2B* in NMDAR subunit has been taken as evidence for an important role in brain development, circuit formation, and possibly cell migration and differentiation⁶⁷. In early postnatal development and late embryogenesis, GluN2B expression dominates during rapid cortical synaptogenesis⁶⁸. Kutsuwada *et al.* observed neonate lethality of global *GRIN2B* knockout mice⁶⁹, whereas Tang *et al.* reported that overexpression of *GRIN2B* in the forebrain of mice enhanced spatial memory performance and long-term hippocampal potentiation⁷⁰.

It is not surprising that the many recent reports on human variants in *GRIN* genes show different clinical phenotypes (discussed below) given that the modular structure of the receptor can compartmentalize the different actions of variants in different domains, thereby impacting different functional modalities. In addition, the distinct roles of GluN2A and GluN2B in synaptic signaling and circuit function enabled by their different developmental expression profile^{58,61–63}, the compartmentalization⁶², and the functional attributes mean that variants in these two genes could have very different effects and different age-dependent phenotypes. For example, more pronounced effects might be observed for *GRIN2B* variants in terms of neurodevelopment, and effects of the mutations might present early in postnatal stages and manifest as neurodevelopmental disorders, developmental delays (DDs), and intellectual disability (ID)⁷¹. However, the effect of *GRIN2A* will start to show in the later postnatal stage as the expression of *GRIN2A* starts to increase and thus the influence of GluN2A-containing NMDARs becomes important. Most of the GluN2A variants were identified in patients with epileptic seizures and epileptic

encephalopathies⁷². In most cases when variants reduce Mg^{2+} inhibition and otherwise show enhanced NMDAR function, the patients show epileptic encephalopathy (EE), which may reflect not just DD from persistent and intractable seizures but perhaps excitotoxic neuronal cell death⁷³. Interestingly, variants in GluN1 will impact all NMDARs and thus would be expected to have even further distinct effects compared with *GRIN2A* and *GRIN2B*⁷⁴. However, in this review, we restrict our summary of recent studies to rare *de novo* variants discovered in the *GRIN2A* and *GRIN2B* genes. We highlight an emerging understanding of the functional and clinical consequences of these variants in the context of receptor expression, localization, and the unique roles that GluN2A and GluN2B subunits play. We speculate that viewing the phenotypic differences for patients with *GRIN2A* and *GRIN2B* through the lenses of these different properties will provide greater insight into disease mechanism and this information will create the possibility of instituting mechanism-based novel therapeutic treatments.

The increase in genetic information identifies a large number of disease-associated variants

The number of rare variants associated with neurological disease is expanding rapidly. Since the identification of the first disease-causing variants in NMDARs in 2010^{75,76}, over 500 variants in all *GRIN* genes coding for NMDARs—found in all four semi-autonomous domains, (the ATD, the ABD, the TMD, and the CTD)—have been reported in ClinVar or from patient cohorts in the literature. These include 249 variants in the *GRIN2A* and 204 variants in the *GRIN2B* (ClinVar). The increasing use of next-generation whole exome sequencing in clinical practice promises to identify even more rare *de novo* variants in *GRIN* genes linked to neurological disorders as diagnostic whole exome sequencing efforts expand and become common practice outside academic medical centers^{71,77,78}. The rapid identification of numerous rare genetic variants should be followed by functional analysis of these variants, which, though more time-intensive, is an essential step in establishing their role in neurological disease. In addition, functional evaluation provides mechanistic insight toward disease etiology and potential treatment options. Fortunately, the NMDARs encoded by these genes can be easily expressed in heterologous systems and their function, though complex, is reasonably well understood^{1,2,6}. Multiple groups are expanding efforts to fill the gap between genetic identification of rare variants and elucidation of their functional consequences^{6,23,73,74,79–98}. With continued effort, all disease-associated variants eventually should be identified and functional characterization of these variants will inform the subdivision of variants into a limited set of groups with more homogenous clinical and functional phenotypes. This will allow direct comparison of variants with similar effects between different subunits and help elucidate the roles that these subunits play during development. It will also transform diagnoses and treatment options since variant function eventually will be readily available for clinicians in real time. However, at the moment, there remains a significant lag in efforts to obtain this functional information compared with the amount of new sequencing being performed.

Comparison of patient phenotype for *GRIN2A* and *GRIN2B* missense and nonsense variants

Among the variants identified in the *GRIN* gene family, those in *GRIN2A* (46%) and *GRIN2B* (38%) account for the vast majority, followed by *GRIN1* variants (14%; ClinVar)⁷². It is important to note that all of these genes can co-assemble to form functional receptors, meaning that the *GRIN* variants should be thought of as a larger set of variants since variants in all three genes can produce similar gain-of-function (GoF) or loss-of-function (LoF) effects on NMDARs. Moreover, every NMDAR contains GluN1 and thus these variants in particular will impact both GluN2B- and GluN2A-containing NMDARs. However, there will be differences in the overall effects for *GRIN2A* versus *GRIN2B* genes depending on their regional and developmental expression profile, in addition to the different roles that they can play in circuit function. Thus, it will be useful to stratify variants by gene and by GoF and LoF even though they impact an overlapping set of NMDAR complexes expressed in the brain. Given that the most common *GRIN* variants are in *GRIN2A* and *GRIN2B*, a comprehensive evaluation of these two subunits provides an opportunity to understand the structural, functional, and genetic bases for disorders that these patients have. Functional consequences of many *GRIN2A* and *GRIN2B* variants have been assessed in heterologous expression systems and so we will focus on the effects of rare variants in these two genes.

An assessment of the genetic variation in the healthy population together with an evaluation of *GRIN2A* and *GRIN2B* variants in patients with neurological disease provides information about the regional tolerance of different domains of the GluN2 subunit. This approach reveals insight into protein function and information about the regions of the receptor that cannot tolerate even modest changes in amino acid side chain properties⁸¹. Such regions appear to have undergone purifying selection and this determination can aid in future *in silico* predictions of the impact of missense variants. Evaluation of *GRIN2A* and *GRIN2B* revealed that the ABD, TMDs, and the linker regions between these domains were particularly intolerant to genetic variation and suggests that these domains are under greater selection pressure^{82,83}. These two regions appear to harbor the most disease-associated variants within the *GRIN2A* and *GRIN2B* genes^{72,82–84}. Evaluation of phenotypic severity for a cohort of patients harboring *GRIN2A* variants showed stratification in severity across variants with different functional effects and localizations⁸⁵. There are some subtle differences in regions that are insensitive to variation that reflects different functions of GluN2A and GluN2B subunits. There are examples where different patients (that is, different genetic backgrounds) harbor the same *de novo* *GRIN* missense variant in their genome; in these cases, the patients display similar but non-identical clinical phenotypes^{21,23,84–88}. As the databases of genetic variation within the standing population expand, there will be an ever-increasing precision with which we can define intolerant regions, and we expect that more specific examples of intolerant regions that differ between the two subunits will emerge. In this review, we also compiled a list of *GRIN2A* and *GRIN2B* variants with phenotypes

published in the literature and not found in the gnomAD database (<http://gnomad.broadinstitute.org>; Table 1).

GRIN2A predominantly is associated with epilepsy and intellectual disability

More than 240 missense and nonsense variants have been reported for *GRIN2A*. *De novo* variants in *GRIN2A* can be found in phenotypically normal neonates with a structurally normal brain at birth^{85,89}. Multiple patients appear to have had uncomplicated pregnancies and normal deliveries with excellent appearance, pulse, grimace, activity, respiration (APGAR) scores and no immediate complications. However, patients can begin to show neurological abnormalities at a young age (during the first year of life)⁸⁹, presumably as a result of increasing expression of *GRIN2A* with development⁶⁰. This most often manifests as abnormal electroencephalography (EEG) and myoclonic jerks progressing to a seizure disorder. Several studies

have suggested that benign focal epilepsy with centrotemporal spikes (BECTS) seems to be caused by both missense and nonsense *de novo* mutations within the *GRIN2A* gene: Three reports from 2013 showed that *GRIN2A* gene variants are more likely to occur in epilepsy subtypes that are believed to be a more severe variant of BECTS such as atypical benign partial epilepsy of childhood, Landau-Kleffner syndrome, and continuous spike waves during slow wave sleep^{99–101}. An intriguing aspect of these epilepsy patients who harbor *GRIN2A* variants is that the variants can produce both GoF and LoF, as inferred by nonsense variants that produce protein truncation. Patients with a deletion that removes the *GRIN2A* gene also show hyperexcitability⁷⁶. The mechanisms that ultimately promote hyperexcitability in patients lacking *GRIN2A* are not yet known, by likely due to haploinsufficiency although it appears that they in some way enhance circuit excitability¹⁰². Interestingly, there is no firm evidence to suggest that *GRIN2A* variants

Table 1. Phenotypes reported across *GRIN2A* and *GRIN2B* subdomains.

Phenotypes (top) or Variant Type (bottom)	# reported in <i>GRIN2A</i> / # reported in <i>GRIN2B</i>					
	ATD	ABD	ABD-TMD Linkers	TMD	CTD	Other
Epi	25 / 3	41 / 13	5 / 4	19 / 12	9 / 0	26 / 1
ID	28 / 13	32 / 35	4 / 9	19 / 23	8 / 9	22 / 15
ASD	4 / 6	5 / 13		4 / 3	2 / 6	1 / 5
Language delay/Verbal dyspraxia/Aphasia syndrome	14 / 0	22 / 0	5 / 1	10 / 0	1 / 1	7 / 0
LKS	1 / 0	3 / 0	1 / 0		1 / 0	1 / 0
ADHD/Rett-like syndrome/Behaviorial anomalies	2 / 1	3 / 0	1 / 1	1 / 1		1 / 2
IS	1 / 0	1 / 0		0 / 2		
CVI				1 / 3		
Hypotonia/Dystonia	3 / 0	0 / 1	0 / 1	9 / 1		2 / 1
LGS		0 / 1				
MD		3 / 1	3 / 1	4 / 2		1 / 0
West syndrome		0 / 1		0 / 2		
Dysmorphic features	1 / 0	1 / 0	0 / 1	2 / 1		3 / 0
SCZ/Bipolar disorder	1 / 2				1 / 2	2 / 0
Macrocephaly or Abnormality of nervous system					1 / 1	3 / 1
Missense variant	12 / 7	31 / 29	4 / 8	20 / 23	7 / 8	
Nonsense variant	8 / 4	3 / 2	0 / 1	0 / 2	3 / 2	
Splice junction variant	9 / 0	7 / 3	1 / 0	0 / 1		
Frame-shift variant	5 / 4	9 / 1		4 / 0	2 / 3	
Indel variant			1 / 0		1 / 1	
Other						31 / 17

The table compares genetic variants in *GRIN2A* and *GRIN2B* genes with phenotypes as reported in the literature and absent in the gnomAD database (<http://gnomad.broadinstitute.org>). ABD, agonist-binding domain; ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; ATD, amino-terminal domain; CTD, carboxyl-terminal domain; CVI, cerebral visual impairment; Epi, epilepsy/seizures; ID, intellectual disability (including developmental delay); IS, infantile spasms; LGS, Lennox-Gastaut syndrome; LKS, Landau-Kleffner syndrome; MD, movement disorder; SCZ, schizophrenia; and TMD, transmembrane domains (M1-M4). Other, refers to chromosome deletions, insertions, duplications that affect *GRIN2A* or *GRIN2B* genes. References 21, 73, 75, 76, 80, 82–86, 89–92, 94, 96, 98–101, 103–153.

contribute to the two most common epilepsy syndromes: idiopathic generalized epilepsy and temporal lobe epilepsy¹⁵⁴. *GRIN2A* variants are linked to autism spectrum disorder (ASD) but to a lesser degree than seen with *GRIN2B* variants (Table 1).

GRIN variants have been identified both by screening of a select set of genes assembled as a panel or by whole exome sequencing, which provides good coverage over much of the exome, although certain GC-rich regions of DNA (for example, the 5' region of *GRIN2D*) are often under-represented. Nevertheless, these approaches have discovered a large number of *de novo* variants in neurological patients. A functional analysis has been published in the peer-reviewed literature for a number of *GRIN2A* variants^{73,75,79,83,86,90-93}. In addition, there is a comprehensive functional summary on the websites as a resource (<http://functionalvariants.emory.edu>). Below, a subset of these published variants is discussed to illustrate some important commonalities and distinctions.

The functional consequences of several variants reported in the gnomAD database, some of which showed functional changes, were evaluated. One clinical case report is for a missense variant (GluN2A-V452M) from a patient with early infantile EE/Ohtahara syndrome¹⁵⁵. Another example of a variant proposed to cause a disease phenotype is a heterozygous *GRIN2A* variant that produces GluN2A-N447K in a male with Rolandic epilepsy. EEG monitoring showed remarkable interictal high voltage spikes and spike-and-slow waves in the bilateral central-temporal regions, predominantly on the right hemisphere. The GluN2A-N447K variant is located in the S1 segment of the extracellular ABD of GluN2A. Residue N447 is highly conserved across higher vertebrates yet the Asn447Lys variant is present multiple times in gnomAD. Whole cell patch clamp recording of GluN2A-N447K reveals a GoF effect and an increase in NMDAR current density by about 1.2-fold, an enhancement of glutamate potency by two fold, and reduced sensitivity to Mg²⁺ inhibition⁹³. Experimental substitution of Asn447 to alanine (uncharged) or glutamic acid (negatively charged) did not change NMDAR function, suggesting that the positive charge associated with lysine may have altered NMDAR function. The patient became seizure-free when treated with a combination of valproate and lamotrigine⁹³.

A child with epileptic encephalopathy (EE) and severe cognitive impairment possessed a GoF missense *GRIN2A* variant that produced GluN2A-L812M. This position in the linker between the ABD and TMD regions is intolerant to change, as all amino acid substitutions (seven to date) at this position produced a GoF variant that showed increased agonist potency, increased open probability, and reduced sensitivity to endogenous negative modulators such as extracellular Mg²⁺ and protons⁷³. The variant NMDARs' activities were enhanced by virtually every measure and would be expected to lead to profound overactivation, which could drive excitotoxic mechanisms. Memantine is able to inhibit the GluN2A-L812M-containing NMDARs, and treatment with memantine led to a persistent reduction of the child's seizure burden⁸⁹.

A heterologous *de novo* variant was found in a 3-year-old female with early-onset EE, abnormal EEG, and severe DD⁷⁵. The variant substituted an evolutionarily conserved asparagine for a lysine (GluN2A-N615K) in the membrane re-entrant loop, which lines the channel pore and creates a constriction that controls ion selectivity of the channel^{6,156,157}. This variant alters the voltage-dependent channel block by Mg²⁺ and decreases in Ca²⁺ permeability. Co-expression of GluN2-N615K with GluN1 and wild-type GluN2A in the same receptor complex, called triheteromeric receptors (comprised of GluN1:GluN2A:GluN1:GluN2A-N615K subunits), produces an intermediate effect, indicating that the negative impact caused by the variant on channel properties cannot be fully negated by the presence of one normal subunit copy of GluN2A in the receptor complex^{21,92}.

GRIN2B is predominantly associated with developmental delay, intellectual disability, and autism spectrum disorder

Over 200 variants in *GRIN2B* are found in patients from cohorts with any one of several neurodevelopmental disorders⁷¹ such as ID (including DD)^{14,75,80,82-84,91,94-96,98,103-108,111,112,114,120,122,123,128,130,135,139-147,149-153}, ASD^{75,80,82,84,91,98,104,105,108,111,135,140,144,148,151-153}, EE and seizure disorders^{21,80,82,84,98,103,120,130,135,138,139,141,145}, schizophrenia^{71,111,114,137,148}, and, to a lesser extent, attention-deficit/hyperactivity disorder^{80,84,106}, cerebral visual impairment^{146,158}, and Alzheimer's disease¹⁵⁹ have been reported in the literature. For these various phenotypes, virtually all of the patients display mild to profound DD or ID or both. In addition to exhibiting these neurological phenotypes, some patients exhibit abnormalities in muscle tone that includes spasticity or hypotonia^{151,158}. *GRIN2B* has been linked as a potential gene in which variations could increase the risk of autism^{104,105,160}. A number of other characteristics, including microcephaly, movement disorders, Rett-like syndrome, language disorders have been observed in some patients^{75,96,115,142,158}.

The *GRIN2B* variants identified thus far occur throughout the entire NMDAR subunit protein. That is, missense and non-sense variants have been identified in the ABD, TMD, and CTD domains. Homozygous *Grin2b*-deletion mice die at early postnatal stages because of impaired suckling response and show impaired hippocampal long-term depression, whereas heterozygous mice show reduced expression of GluN2B but survive⁶⁹. Thus, *GRIN2B* is an essential gene for normal development. *GRIN2B de novo* variants with neurological diseases have been reviewed^{71,77,161}, and functional data exist for many *GRIN2B* variants in published scientific journals (see below) or online databases (<http://functionalvariants.emory.edu>).

Large cohort studies for ID or ASD have identified that LoF variants in *GRIN2B* segregate with a broad spectrum of these neurological phenotypes^{75,105}. One such LoF variant is the missense variant GluN2B-E413G¹⁰⁶, which produces DD and ID. Studies conducted on neural progenitor cells (NPCs) generated from induced pluripotent stem cells found that neurons with heterozygous GluN2B-E413G, which is in the glutamate-binding pocket, caused a 50-fold decrease in glutamate signaling and reduced the maturation states of the

neurons. Verification of failure to phosphorylate serine 133 in cAMP response element-binding protein (CREB) by NMDAR stimulation further confirms that the E413G variant in GluN2B impaired NMDAR signaling in the NPCs⁹⁴. This study shows that *GluN2B*-containing NMDARs are critical for signal transduction in neural stem cells and deficits in this process impair cellular differentiation. The E413G variant is in close proximity to the glutamate-binding site but is not in physical contact with the agonist glutamate. Modelling of the protein structure suggests that GluN2B-E413 can alter agonist dissociation by increasing the ability of water to compete with agonist binding, thereby accelerating glutamate unbinding and likely rendering the synaptic NMDAR response time course briefer than that for wild-type NMDARs^{82,95}.

The *GRIN2B* variant encoding GluN2B-C461F, which was identified in a patient with Lennox–Gastaut syndrome and autistic features, is a LoF NMDAR variant. Cys461 is located in S1 of the ABD, close to the orthosteric glutamate-binding site. When co-transfected with GluN1-4b, an early developmental isoform of *GRIN1*, GluN1:GluN2B-C461F receptors reduced glutamate potency by 71-fold compared with wild-type controls⁸⁰. This is in keeping with decreased glutamatergic neurotransmission in animal models of ASD (for example, BTBR mice), in which the phenotype can be improved by a selective AMPAKINE (AMPA receptor-positive allosteric modulator). Lennox–Gastaut syndrome is a severe type of childhood epilepsy. Also, during early development, high expression of variant GluN2B subunits could compromise neurotransmitter-based signaling (for example, GABA release via presynaptic NMDARs), circuit operation between distinct cell types (interneurons/principal neurons), and the balance of excitation and inhibition⁸⁰. This is in line with the association of mutations in *GABRB3* with Lennox–Gastaut syndrome and autism^{162–164}. In addition, synaptic pruning and synapse refinement are GluN2-dependent events that occur generally at a time of a switch in subunit expression from GluN2B to GluN2A⁶⁴ and thus could be influenced by altered GluN2B function. This could be one contributing factor that is an underlying substrate for developmental effects of *GRIN2B* variants¹⁶⁵.

The GluN2B-P553L variant was identified in a patient with severe ID¹⁰⁷. This variant was found to minimally affect glutamate potency, but the rate of desensitization of GluN1–GluN2B-P553L was markedly increased and currents were small in HEK cells^{80,83}. Pro553 is located at the proximal end of the first TMD, within the pre-M1 linker that connects S1 to M1. Spatially, P553 is adjacent to the highly conserved nine-residue signal-transduction element (SYTANLAAF) in M3 of the same subunit, which is involved in coupling ligand binding to channel opening, and controls channel open probability⁶. Thus, the variant Pro553Leu may form different interactions with Asn649 or Leu650 (or both) in the SYTANLAAF motif, which could interfere with gating.

GluN2B-N615I and GluN2B-V618G variants are both associated with West syndrome, which is a triad of infantile spasms,

hypsarhythmia, and ID¹⁰³. GluN2B-N615 and -V618 are located in the M2 re-entrant loop, which forms part of the ion channel. N615 is located just above the narrowest constriction in the pore, which is also influenced by analogous residues in the GluN1 subunit (for example, GluN1-N616). Val618 in GluN2B is located deep in the channel pore, within the M2-M3 linker and with the CH₃ side chain that has been suggested to be rotated away from the channel pore. This side-chain will interact with residues in M2 and M3 membrane helices of GluN1^{80,98}. For GluN2B-N615I and GluN2B-V618G, voltage-dependent Mg²⁺ inhibition was lost, resulting in a GoF phenotype that will allow increased NMDAR current under normal resting conditions, which may underlie increased neuronal excitability in West syndrome. The onset of symptoms in the patient coincided with the high expression profile of GluN2B in late infancy (<1 year old)^{92,103}.

Variants at the same residue position in GluN2A and GluN2B resulted in different disease phenotypes

A variant in both *GRIN2A* and *GRIN2B* that occurs at the same homologous position of these GluN2 subunits in NMDAR has been identified. Functionally, both GluN2A-N615K and GluN2B-N615I and GluN2B-N615K variants that substitute an evolutionarily conserved asparagine in the membrane re-entrant loop resulted in a loss of Mg²⁺ block^{21,75,80,84}. However, the resulting neurological phenotypes were found to be different. A 3-year-old female with a GluN2A-N615K variant exhibits early-onset EE, an abnormal EEG, and a severe DD⁷⁵, whereas for a GluN2B-N615I variant, the patient had West syndrome, hypsarhythmia, and ID due to neurodevelopmental disorders^{80,84} and GluN2B-N615K patient had ID and DD⁸⁴. This further validates our hypothesis that rare variants in intolerant domains in *GRIN2A* are more likely to cause an epileptic phenotype but that variants in *GRIN2B* are more aligned with abnormal developmental phenotypes.

Other cases for which the genetic variants were found on different GluN2 subunits at a homologous amino acid are GluN2A-P552R and GluN2B-P553L. GluN2A-P552R was identified in a patient with delayed psycho-motor development, ID, inability to speak, and epilepsy since 9 months of age^{83,107}. The GluN2A-P552R variant shows increased sensitivity to glutamate and glycine but with a slower activation and deactivation time course. The GluN2B-P553L variant presents in a patient with severe ID and DD^{80,83,98,107}. This variant was found to reduce glutamate potency by 1.7-fold but increase the rate of glutamate current desensitization^{80,83}. Thus, whereas one variant should increase charge transfer for each synaptic current, the other should diminish it.

In most situations, the GluN2A or GluN2B variants exist as a single allele (that is, are heterozygous) in the patients and therefore patients also have one copy of the wild-type allele. Therefore, it would be important to understand the effects of rare variants in both diheteromeric and triheteromeric NMDARs. As the NMDARs exist as a heterotetramer with two obligatory GluN1 subunits, the possibility exists that a diheteromer (for example, GluN1/GluN2A/GluN1/GluN2A) or

triheteromer (for example, GluN1/GluN2A/GluN1/GluN2B) harbors a single disease variant GluN2 subunit.

To understand the *GRIN2* variant effects in the presence of wild-type allele, NMDAR subunits were engineered to co-express as GluN1/GluN2A/GluN1/GluN2A-P552R and GluN1/GluN2A-P552R/GluN1/GluN2A-P552R, analyzed for response time course to glutamate and glycine, and compared with wild-type control GluN1/GluN2A. Single channel recording from single copy variant-containing receptors did not alter mean channel open time or chord conductance as compared with the wild-type channel. For the NMDARs with two copies of GluN2A-P552R, there is a significant increase in mean open time and reduced channel conductance when compared with the wild-type or single copy mutant. These data suggest that the GluN2A-P552R variants can alter stability and conformation of the open pore or its access portals only when both GluN2A subunits contain the P552R variant⁸³.

Precision medicine


As more precise diagnoses for individuals are achieved, the basis of disease etiology will be better defined. We anticipate that novel drug development and a more mechanism-based use of currently approved drugs can improve clinical outcomes. For pharmacological treatment, the knowledge of risk factors, disease subtype, or underlying genetic variation should allow a choice of therapies proven effective in individuals with similar characteristics. For rare variants that are thought to contribute to or cause a disease, unique treatments that alter the function of the target or its downstream effects could provide novel therapies. This collection of ideas together can be described as precision medicine, an idea that is enabled by recent advances in technology on multiple fronts. There are several opportunities for potential precision medicine among the *GRIN* variants. For example, it seems reasonable that therapies already approved by the US Food and Drug Administration that inhibit NMDAR receptors might have utility against symptoms produced by GoF *GRIN* variants provided that some of the ongoing neurological symptoms reflect expression of aberrant protein rather than errant processes during development or cell loss driven by excitotoxicity. Likewise, although there are no currently available NMDAR potentiators approved for clinical use, supplementation with the co-agonists glycine, D-serine, or perhaps D-cycloserine might provide a way to augment NMDAR function, although

there remains no systematic evaluation of this possibility in animal models or patients⁹⁶.

Personalized medicine through pharmacological intervention on patients harboring *de novo GRIN2A* and *GRIN2B* variants has been attempted. However, caution must be exercised as the potential drugs available (for example, memantine) are non-selective blockers of NMDARs, meaning that one may induce a block at some sites that are not contributing to the pathology. Memantine binding was also affected by the presence of bound Mg^{2+} in the channel, which reduced memantine potency more for GluN2A and GluN2B than GluN2C or GluN2D¹⁶⁶. Kinetic and molecular docking results indicated overlapping sites for Mg^{2+} and memantine, with Mg^{2+} binding at the level of the asparagine residues, whereas memantine binds just above the channel pore¹⁶⁷. Among the NMDAR subtypes, memantine has been suggested to be more potent at GluN2C- and GluN2D-containing NMDARs, the latter of which are expressed in GABAergic interneurons^{53,168}. Nevertheless, over-active receptors may be attenuated, and some degree of voltage-dependent block potentially restored, to compensate for a reduced Mg^{2+} block by a rare variant. However, again caution is emphasized as several distinct disease variants in the channel pore can also alter the effect of candidate therapies, and already there are examples among the *GRIN* genes in which the variant renders a potential drug candidate less effective. For example, memantine was more potent at GluN1/GluN2B-N615I and less potent at GluN1/GluN2B-V618G, compared with wild-type receptors, which holds important implications for therapeutics. Interestingly, dextromethorphan showed increased potency for some variant receptors compared with wild-type receptors⁹⁰.

Of the various mutations studied in detail, two result in LoF (C461F and P553L) and two in GoF (N615I and V618G). On this basis, memantine cannot be considered an all-encompassing treatment for NMDAR mutations and will be therapeutically beneficial for only selected GoF channel variants unless compensatory NMDAR is large. Still, there are some examples in which NMDAR block by memantine showed some utility^{86,89,97}. The inhibition of NMDAR-mediated currents by memantine at negative membrane potentials was comparable between wild-type and N615I- or V618G-expressing neurons. This supports a role for this medication as a potential therapy to mimic a loss Mg^{2+} block at the potentials in neurons.

References

1. Traynelis SF, Wollmuth LP, McBain CJ, *et al.*: **Glutamate receptor ion channels: structure, regulation, and function.** *Pharmacol Rev.* 2010; **62**(3): 405–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Paoletti P, Bellone C, Zhou Q: **NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.** *Nat Rev Neurosci.* 2013; **14**(6): 383–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Ryan TJ, Emes RD, Grant SG, *et al.*: **Evolution of NMDA receptor cytoplasmic interaction domains: implications for organisation of synaptic signalling complexes.** *BMC Neurosci.* 2008; **9**: 6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Ryan TJ, Kopaniitsa MV, Indersmitten T, *et al.*: **Evolution of GluN2A/B cytoplasmic domains diversified vertebrate synaptic plasticity and behavior.** *Nat Neurosci.* 2013; **16**(1): 25–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5.  Wang JX, Furukawa H: **Dissecting diverse functions of NMDA receptors by**



- structural biology.** *Curr Opin Struct Biol.* 2019; **54**: 34–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
6. Hansen KB, Yi F, Perszyk RE, *et al.*: **Structure, function, and allosteric modulation of NMDA receptors.** *J Gen Physiol.* 2018; **150**(8): 1081–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 7. Karakas E, Regan MC, Furukawa H: **Emerging structural insights into the function of ionotropic glutamate receptors.** *Trends Biochem Sci.* 2015; **40**(6): 328–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Armstrong N, Sun Y, Chen GQ, *et al.*: **Structure of a glutamate-receptor ligand-binding core in complex with kainate.** *Nature.* 1998; **395**(6705): 913–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 9. Armstrong N, Gouaux E: **Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core.** *Neuron.* 2000; **28**(1): 165–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 10. Sobolevsky AI, Rosconi MP, Gouaux E: **X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor.** *Nature.* 2009; **462**(7274): 745–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 11. Yelshanskaya MV, Mesbahi-Vasey S, Kurnikova MG, *et al.*: **Role of the Ion Channel Extracellular Collar in AMPA Receptor Gating.** *Sci Rep.* 2017; **7**(1): 1050.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Lee CH, Lü W, Michel JC, *et al.*: **NMDA receptor structures reveal subunit arrangement and pore architecture.** *Nature.* 2014; **511**(7508): 191–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Karakas E, Furukawa H: **Crystal structure of a heterotetrameric NMDA receptor ion channel.** *Science.* 2014; **344**(6187): 992–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 14. Glasgow NG, Siegler Retchless B, Johnson JW: **Molecular bases of NMDA receptor subtype-dependent properties.** *J Physiol.* 2015; **593**(1): 83–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Wollmuth LP, Kuner T, Seeburg PH, *et al.*: **Differential contribution of the NR1- and NR2A-subunits to the selectivity filter of recombinant NMDA receptor channels.** *J Physiol.* 1996; **491**(Pt 3): 779–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Schneggenburger R, Ascher P: **Coupling of permeation and gating in an NMDA-channel pore mutant.** *Neuron.* 1997; **18**(1): 167–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Zuo J, de Jager PL, Takahashi KA, *et al.*: **Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene.** *Nature.* 1997; **388**(6644): 769–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Krupp JJ, Vissel B, Heinemann SF, *et al.*: **N-terminal domains in the NR2 subunit control desensitization of NMDA receptors.** *Neuron.* 1998; **20**(2): 317–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Villarreal A, Regalado MP, Lerma J: **Glycine-independent NMDA receptor desensitization: localization of structural determinants.** *Neuron.* 1998; **20**(2): 329–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Ren H, Honse Y, Karp BJ, *et al.*: **A site in the fourth membrane-associated domain of the N-methyl-D-aspartate receptor regulates desensitization and ion channel gating.** *J Biol Chem.* 2003; **278**(1): 276–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Li J, Zhang J, Tang W, *et al.*: **De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.** *Hum Mutat.* 2019. in press.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Dingledine R, Borges K, Bowie D, *et al.*: **The glutamate receptor ion channels.** *Pharmacol Rev.* 1999; **51**(1): 7–61.
[PubMed Abstract](#)
 23. Chen W, Shieh C, Swanger SA, *et al.*: **GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function.** *J Hum Genet.* 2017; **62**(6): 589–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Gibb AJ, Ogden KK, McDaniel MJ, *et al.*: **A structurally derived model of subunit-dependent NMDA receptor function.** *J Physiol.* 2018; **596**(17): 4057–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. MacDermott AB, Mayer ML, Westbrook GL, *et al.*: **NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones.** *Nature.* 1986; **321**(6069): 519–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Schneggenburger R: **Simultaneous measurement of Ca²⁺ influx and reversal potentials in recombinant N-methyl-D-aspartate receptor channels.** *Biophys J.* 1996; **70**(5): 2165–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Watanabe J, Beck C, Kuner T, *et al.*: **DRPEER: a motif in the extracellular vestibule conferring high Ca²⁺ flux rates in NMDA receptor channels.** *J Neurosci.* 2002; **22**(23): 10209–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Deisseroth K, Heist EK, Tsien RW: **Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons.** *Nature.* 1998; **392**(6672): 198–202.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Bayer KU, de Koninck P, Leonard AS, *et al.*: **Interaction with the NMDA receptor locks CaMKII in an active conformation.** *Nature.* 2001; **411**(6839): 801–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Herring BE, Nicoll RA: **Long-Term Potentiation: From CaMKII to AMPA Receptor Trafficking.** *Annu Rev Physiol.* 2016; **78**: 351–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Bender VA, Bender KJ, Brasier DJ, *et al.*: **Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex.** *J Neurosci.* 2006; **26**(16): 4166–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 32. Sather W, Dieudonné S, MacDonald JF, *et al.*: **Activation and desensitization of N-methyl-D-aspartate receptors in nucleated outside-out patches from mouse neurones.** *J Physiol.* 1992; **450**(1): 643–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Medina I, Filippova N, Charton G, *et al.*: **Calcium-dependent inactivation of heteromeric NMDA receptor-channels expressed in human embryonic kidney cells.** *J Physiol.* 1995; **482**(Pt 3): 567–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Price CJ, Rintoul GL, Baimbridge KG, *et al.*: **Inhibition of calcium-dependent NMDA receptor current rundown by calbindin-D_{28k}.** *J Neurochem.* 1999; **72**(2): 634–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Erreger K, Dravid SM, Banke TG, *et al.*: **Subunit-specific gating controls rat NR1/NR2A and NR1/NR2B NMDA channel kinetics and synaptic signalling profiles.** *J Physiol.* 2005; **563**(Pt 2): 345–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 36. Chen N, Luo T, Raymond LA: **Subtype-dependence of NMDA receptor channel open probability.** *J Neurosci.* 1999; **19**(16): 6844–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Erreger K, Geballe MT, Kristensen A, *et al.*: **Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors.** *Mol Pharmacol.* 2007; **72**(4): 907–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Vicini S, Wang JF, Li JH, *et al.*: **Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors.** *J Neurophysiol.* 1998; **79**(2): 555–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Lester RA, Clements JD, Westbrook GL, *et al.*: **Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents.** *Nature.* 1990; **346**(6284): 565–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Paoletti P, Ascher P, Neyton J: **High-affinity zinc inhibition of NMDA NR1-NR2A receptors.** *J Neurosci.* 1997; **17**(15): 5711–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Traynelis SF, Burgess MF, Zheng F, *et al.*: **Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit.** *J Neurosci.* 1998; **18**(16): 6163–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Rachline J, Perin-Dureau F, Le Goff A, *et al.*: **The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.** *J Neurosci.* 2005; **25**(2): 308–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Groc L, Choquet D: **AMPA and NMDA glutamate receptor trafficking: Multiple roads for reaching and leaving the synapse.** *Cell Tissue Res.* 2006; **326**(2): 423–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Petralia RS, Wang YX, Hua F, *et al.*: **Organization of NMDA receptors at extrasynaptic locations.** *Neuroscience.* 2010; **167**(1): 68–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Sanz-Clemente A, Nicoll RA, Roche KW: **Diversity in NMDA receptor composition: many regulators, many consequences.** *Neuroscientist.* 2013; **19**(1): 62–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Zhou X, Ding Q, Chen Z, *et al.*: **Involvement of the GluN2A and GluN2B subunits in synaptic and extrasynaptic N-methyl-D-aspartate receptor function and neuronal excitotoxicity.** *J Biol Chem.* 2013; **288**(33): 24151–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Won S, Incontro S, Nicoll RA, *et al.*: **PSD-95 stabilizes NMDA receptors by inducing the degradation of STEP61.** *Proc Natl Acad Sci U S A.* 2016; **113**(32): E4736–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 48. Delgado JY, Fink AE, Grant SGN, *et al.*: **Rapid homeostatic downregulation of LTP by extrasynaptic GluN2B receptors.** *J Neurophysiol.* 2018; **120**(5): 2351–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 49. Hardingham GE, Fukunaga Y, Bading H: **Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways.** *Nat Neurosci.* 2002; **5**(5): 405–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 50. Martel MA, Wylie DJ, Hardingham GE: **In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate**

- signaling to neuronal survival and synaptic potentiation, as well as neuronal death. *Neuroscience*. 2009; 158(1): 334–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Soriano FX, Hardingham GE: **Compartmentalized NMDA receptor signalling to survival and death.** *J Physiol*. 2007; 584(Pt 2): 381–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Hardingham GE: **Coupling of the NMDA receptor to neuroprotective and neurodestructive events.** *Biochem Soc Trans*. 2009; 37(Pt 6): 1147–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Monyer H, Burnashev N, Laurie DJ, et al.: **Developmental and regional expression in the rat brain and functional properties of four NMDA receptors.** *Neuron*. 1994; 12(3): 529–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Hatten ME: **Central nervous system neuronal migration.** *Annu Rev Neurosci*. 1999; 22: 511–39.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Medina AE, Liao DS, Mower AF, et al.: **Do NMDA receptor kinetics regulate the end of critical periods of plasticity?** *Neuron*. 2001; 32(4): 553–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Dumas TC: **Developmental regulation of cognitive abilities: modified composition of a molecular switch turns on associative learning.** *Prog Neurobiol*. 2005; 76(3): 189–211.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Monaco SA, Gulchina Y, Gao WJ: **NR2B subunit in the prefrontal cortex: A double-edged sword for working memory function and psychiatric disorders.** *Neurosci Biobehav Rev*. 2015; 56: 127–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Wyllie DJ, Livesey MR, Hardingham GE: **Influence of GluN2 subunit identity on NMDA receptor function.** *Neuropharmacology*. 2013; 74: 4–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Mori H, Mishina M: **Structure and function of the NMDA receptor channel.** *Neuropharmacology*. 1995; 34(10): 1219–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Akazawa C, Shigemoto R, Bessho Y, et al.: **Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.** *J Comp Neurol*. 1994; 347(1): 150–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Shi J, Townsend M, Constantine-Paton M: **Activity-dependent induction of tonic calcineurin activity mediates a rapid developmental downregulation of NMDA receptor currents.** *Neuron*. 2000; 28(1): 103–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. van Zundert B, Yoshii A, Constantine-Paton M: **Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal.** *Trends Neurosci*. 2004; 27(7): 428–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. **F** McKay S, Ryan TJ, McQueen J, et al.: **The Developmental Shift of NMDA Receptor Composition Proceeds Independently of GluN2 Subunit-Specific GluN2 C-Terminal Sequences.** *Cell Rep*. 2018; 25(4): 841–851.e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
64. Bar-Shira O, Maor R, Chechik G: **Gene Expression Switching of Receptor Subunits in Human Brain Development.** *PLoS Comput Biol*. 2015; 11(12): e1004559.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
65. Williams K, Russell SL, Shen YM, et al.: **Developmental switch in the expression of NMDA receptors occurs *in vivo* and *in vitro*.** *Neuron*. 1993; 10(2): 267–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Barth AL, Malenka RC: **NMDAR EPSC kinetics do not regulate the critical period for LTP at thalamocortical synapses.** *Nat Neurosci*. 2001; 4(3): 235–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Cohen S, Greenberg ME: **Communication between the synapse and the nucleus in neuronal development, plasticity, and disease.** *Annu Rev Cell Dev Biol*. 2008; 24: 183–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Hall BJ, Ripley B, Ghosh A: **NR2B signaling regulates the development of synaptic AMPA receptor current.** *J Neurosci*. 2007; 27(49): 13446–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Kutsuwada T, Sakimura K, Manabe T, et al.: **Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor epsilon 2 subunit mutant mice.** *Neuron*. 1996; 16(2): 333–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Tang YP, Shimizu E, Dube GR, et al.: **Genetic enhancement of learning and memory in mice.** *Nature*. 1999; 401(6748): 63–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Hu C, Chen W, Myers SJ, et al.: **Human GRIN2B variants in neurodevelopmental disorders.** *J Pharmacol Sci*. 2016; 132(2): 115–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. XiangWei W, Jiang Y, Yuan H: **De Novo Mutations and Rare Variants Occurring in NMDA Receptors.** *Curr Opin Physiol*. 2018; 2: 27–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Yuan H, Hansen KB, Zhang J, et al.: **Functional analysis of a *de novo* GRIN2A missense mutation associated with early-onset epileptic encephalopathy.** *Nat Commun*. 2014; 5: 3251.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Lemke JR, Geider K, Helbig KL, et al.: **Delimiting the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy.** *Neurology*. 2016; 86(23): 2171–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. **F** Ende S, Rosenberger G, Geider K, et al.: **Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes.** *Nat Genet*. 2010; 42(11): 1021–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
76. Reutlinger C, Helbig I, Gawelczyk B, et al.: **Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region.** *Epilepsia*. 2010; 51(9): 1870–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Burnashev N, Szepietowski P: **NMDA receptor subunit mutations in neurodevelopmental disorders.** *Curr Opin Pharmacol*. 2015; 20: 73–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
78. Yuan H, Low CM, Moody OA, et al.: **Ionotropic GABA and Glutamate Receptor Mutations and Human Neurologic Diseases.** *Mol Pharmacol*. 2015; 88(1): 203–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. Sibarov DA, Bruneau N, Antonov SM, et al.: **Functional Properties of Human NMDA Receptors Associated with Epilepsy-Related Mutations of GluN2A Subunit.** *Front Cell Neurosci*. 2017; 11: 155.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Fedele L, Newcombe J, Topf M, et al.: **Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties.** *Nat Commun*. 2018; 9(1): 957.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Traynelis J, Silk M, Wang Q, et al.: **Optimizing genomic medicine in epilepsy through a gene-customized approach to missense variant interpretation.** *Genome Res*. 2017; 27(10): 1715–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
82. Swanger SA, Chen W, Wells G, et al.: **Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains.** *Am J Hum Genet*. 2016; 99(6): 1261–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Ogden KK, Chen W, Swanger SA, et al.: **Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.** *PLoS Genet*. 2017; 13(1): e1006536.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Platzer K, Yuan H, Schütz H, et al.: **GRIN2B encephalopathy: Novel findings on phenotype, variant clustering, functional consequences and treatment aspects.** *J Med Genet*. 2017; 54(7): 460–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. **F** Strehlow V, Heyne HO, Vlaskamp DR, et al.: **GRIN2A-related disorders: Genotype and functional consequence predict phenotype.** *Brain*. 2019; 142(1): 80–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. Fernández-Marmiesse A, Kusumoto H, Rekart S, et al.: **A novel missense mutation in GRIN2A causes a nonepileptic neurodevelopmental disorder.** *Mov Disord*. 2018; 33(6): 992–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
87. Li D, Yuan H, Ortiz-Gonzalez XR, et al.: **GRIN2D Recurrent De Novo Dominant Mutation Causes a Severe Epileptic Encephalopathy Treatable with NMDA Receptor Channel Blockers.** *Am J Hum Genet*. 2016; 99(4): 802–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Fry AE, Fawcett KA, Zelnik N, et al.: **De novo mutations in GRIN1 cause extensive bilateral polymicrogyria.** *Brain*. 2018; 141(3): 698–712.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Pierson TM, Yuan H, Marsh ED, et al.: **GRIN2A mutation and early-onset epileptic encephalopathy: Personalized therapy with memantine.** *Ann Clin Transl Neurol*. 2014; 1(3): 190–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
90. Chen W, Tankovic A, Burger PB, et al.: **Functional Evaluation of a De Novo GRIN2A Mutation Identified in a Patient with Profound Global Developmental Delay and Refractory Epilepsy.** *Mol Pharmacol*. 2017; 91(4): 317–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. **F** Amin JB, Leng X, Gochman A, et al.: **A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca²⁺ permeability.** *Nat Commun*. 2018; 9(4): 3748.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
92. **F** Marwick KF, Hansen KB, Skehel PA, et al.: **Functional assessment of trimeric NMDA receptors containing a human variant associated with epilepsy.** *J Physiol*. 2019; 597(6): 1691–704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
93. Xu XX, Liu XR, Fan CY, et al.: **Functional Investigation of a GRIN2A Variant Associated with Rolandic Epilepsy.** *Neurosci Bull*. 2018; 34(2): 237–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. **F** Bell S, Maussion G, Jefri M, et al.: **Disruption of GRIN2B Impairs Differentiation in Human Neurons.** *Stem Cell Reports*. 2018; 11(1): 183–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
95. Wells G, Yuan H, McDaniel MJ, et al.: **The GluN2B-Glu413Gly NMDA receptor variant arising from a *de novo* GRIN2B mutation promotes ligand-unbinding and domain opening.** *Proteins*. 2018; 86(12): 1265–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

96. Soto D, Olivella M, Grau C, *et al.*: I-Serine dietary supplementation is associated with clinical improvement of loss-of-function *GRIN2B*-related pediatric encephalopathy. *Sci Signal*. 2019; 12(586): eaaw0936.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. XiangWei W, Kannan V, Xu Y, *et al.*: Heterogeneous Clinical and Functional Features of *GRIN2D*-related Developmental and Epileptic Encephalopathy. *Brain*. in press.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Vyklicky V, Krausova B, Cerny J, *et al.*: Surface Expression, Function, and Pharmacology of Disease-Associated Mutations in the Membrane Domain of the Human GluN2B Subunit. *Front Mol Neurosci*. 2018; 11: 110.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. **F** Carvill GL, Regan BM, Yendle SC, *et al.*: *GRIN2A* mutations cause epilepsy-aphasia spectrum disorders. *Nat Genet*. 2013; 45(9): 1073–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
100. **F** Lemke JR, Lal D, Reinthaler EM, *et al.*: Mutations in *GRIN2A* cause idiopathic focal epilepsy with rolandic spikes. *Nat Genet*. 2013; 45(9): 1067–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
101. **F** Lesca G, Rudolf G, Bruneau N, *et al.*: *GRIN2A* mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. *Nat Genet*. 2013; 45(9): 1061–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
102. Salmi M, Bolbos R, Bauer S, *et al.*: Transient microstructural brain anomalies and epileptiform discharges in mice defective for epilepsy and language-related NMDA receptor subunit gene *Grin2a*. *Epilepsia*. 2018; 59(10): 1919–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Lemke JR, Hendrickx R, Geider K, *et al.*: *GRIN2B* mutations in west syndrome and intellectual disability with focal epilepsy. *Ann Neurol*. 2014; 75(1): 147–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Kenny EM, Cormican P, Furlong S, *et al.*: Excess of rare novel loss-of-function variants in synaptic genes in schizophrenia and autism spectrum disorders. *Mol Psychiatry*. 2014; 19(8): 872–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. **F** O’Roak BJ, Deriziotis P, Lee C, *et al.*: Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. *Nat Genet*. 2011; 43(6): 585–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
106. Adams DR, Yuan H, Holyoak T, *et al.*: Three rare diseases in one Sib pair: *RAI1*, *PCK1*, *GRIN2B* mutations associated with Smith-Magenis Syndrome, cytosolic PEPCCK deficiency and NMDA receptor glutamate insensitivity. *Mol Genet Metab*. 2014; 113(3): 161–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. **F** de Ligt J, Willemsen MH, van Bon BW, *et al.*: Diagnostic exome sequencing in persons with severe intellectual disability. *N Engl J Med*. 2012; 367(20): 1921–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
108. Stessman HA, Xiong B, Coe BP, *et al.*: Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. *Nat Genet*. 2017; 49(4): 515–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. von Stülpnagel C, Ensslen M, Möller RS, *et al.*: Epilepsy in patients with *GRIN2A* alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugs. *Eur J Paediatr Neurol*. 2017; 21(3): 530–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Boutry-Kryza N, Labalme A, Ville D, *et al.*: Molecular characterization of a cohort of 73 patients with infantile spasms syndrome. *Eur J Med Genet*. 2015; 58(2): 51–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Tarabeux J, Kebir O, Gauthier J, *et al.*: Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. *Transl Psychiatry*. 2011; 1: e55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. **F** Grozeva D, Carss K, Spasic-Boskovic O, *et al.*: Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability. *Hum Mutat*. 2015; 36(12): 1197–204.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
113. Serraz B, Grand T, Paoletti P: Altered zinc sensitivity of NMDA receptors harboring clinically-relevant mutations. *Neuropharmacology*. 2016; 109: 196–204.
[PubMed Abstract](#) | [Publisher Full Text](#)
114. Retterer K, Juusola J, Cho MT, *et al.*: Clinical application of whole-exome sequencing across clinical indications. *Genet Med*. 2016; 18(7): 696–704.
[PubMed Abstract](#) | [Publisher Full Text](#)
115. **F** Xiong HY, Alipanahi B, Lee LJ, *et al.*: RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. *Science*. 2015; 347(6218): 1254806.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
116. Addis L, Virdee JK, Vidler LR, *et al.*: Epilepsy-associated *GRIN2A* mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue. *Sci Rep*. 2017; 7(1): 66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
117. DeVries SP, Patel AD: Two patients with a *GRIN2A* mutation and childhood-onset epilepsy. *Pediatr Neurol*. 2013; 49(6): 482–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Conroy J, McGettigan PA, McCreary D, *et al.*: Towards the identification of a genetic basis for Landau-Kleffner syndrome. *Epilepsia*. 2014; 55(6): 858–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Möller RS, Larsen LH, Johannesen KM, *et al.*: Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies. *Mol Syndromol*. 2016; 7(4): 210–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Farwell KD, Shahmirzadi L, El-Khechen D, *et al.*: Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. *Genet Med*. 2015; 17(7): 578–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Allen NM, Conroy J, Shahwan A, *et al.*: Unexplained early onset epileptic encephalopathy: Exome screening and phenotype expansion. *Epilepsia*. 2016; 57(1): e12–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Zhu X, Petrovski S, Xie P, *et al.*: Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. *Genet Med*. 2015; 17(10): 774–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Chen XS, Reader RH, Hoischen A, *et al.*: Next-generation DNA sequencing identifies novel gene variants and pathways involved in specific language impairment. *Sci Rep*. 2017; 7: 46105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Gao K, Tankovic A, Zhang Y, *et al.*: A *de novo* loss-of-function *GRIN2A* mutation associated with childhood focal epilepsy and acquired epileptic aphasia. *PLoS One*. 2017; 12(2): e0170818.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Dymont DA, Tétreault M, Beaulieu CL, *et al.*: Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study. *Clin Genet*. 2015; 88(1): 34–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Gahl WA, Mulvihill JJ, Toro C, *et al.*: The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine. *Mol Genet Metab*. 2016; 117(4): 393–400.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
127. Venkateswaran S, Myers KA, Smith AC, *et al.*: Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, *de novo* *GRIN2A* mutation. *Epilepsia*. 2014; 55(7): e75–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
128. Lelieveld SH, Reijnders MR, Pfundt R, *et al.*: Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat Neurosci*. 2016; 19(9): 1194–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
129. **F** Butler KM, da Silva C, Alexander JJ, *et al.*: Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel. *Pediatr Neurol*. 2017; 77: 61–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
130. Helbig KL, Farwell Hagman KD, Shinde DN, *et al.*: Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med*. 2016; 18(9): 898–905.
[PubMed Abstract](#) | [Publisher Full Text](#)
131. Bramswig NC, Lüdecke HJ, Alanay Y, *et al.*: Exome sequencing unravels unexpected differential diagnoses in individuals with the tentative diagnosis of Coffin-Siris and Nicolai-Baraitser syndromes. *Hum Genet*. 2015; 134(6): 553–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
132. Dimassi S, Labalme A, Lesca G, *et al.*: A subset of genomic alterations detected in rolandic epilepsies contains candidate or known epilepsy genes including *GRIN2A* and *PRRT2*. *Epilepsia*. 2014; 55(2): 370–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
133. Dimassi S, Simonet T, Labalme A, *et al.*: Comparison of two next-generation sequencing kits for diagnosis of epileptic disorders with a user-friendly tool for displaying gene coverage, DeCovA. *Appl Transl Genom*. 2015; 7: 19–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. **F** Green EK, Rees E, Walters JT, *et al.*: Copy number variation in bipolar disorder. *Mol Psychiatry*. 2016; 21(1): 89–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
135. **F** O’Roak BJ, Vives L, Fu W, *et al.*: Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. *Science*. 2012; 338(6114): 1619–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
136. Freunschtl I, Popp B, Blank R, *et al.*: Behavioral phenotype in five individuals with *de novo* mutations within the *GRIN2B* gene. *Behav Brain Funct*. 2013; 9: 20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. Myers RA, Casals F, Gauthier J, *et al.*: A population genetic approach to mapping neurological disorder genes using deep resequencing. *PLoS Genet*. 2011; 7(2): e1001318.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
138. Hildebrand MS, Myers CT, Carvill GL, *et al.*: A targeted resequencing gene panel for focal epilepsy. *Neurology*. 2016; 86(17): 1605–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

139. **F** Epi4K Consortium; Epilepsy Phenome/Genome Project, Allen AS, *et al.*: **De novo mutations in epileptic encephalopathies.** *Nature.* 2013; **501**(7466): 217–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
140. O’Roak BJ, Stessman HA, Boyle EA, *et al.*: **Recurrent de novo mutations implicate novel genes underlying simplex autism risk.** *Nat Commun.* 2014; **5**: 5595.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Fokstuen S, Makrythanasis P, Hammar E, *et al.*: **Experience of a multidisciplinary task force with exome sequencing for Mendelian disorders.** *Hum Genomics.* 2016; **10**(1): 24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
142. Lucariello M, Vidal E, Vidal S, *et al.*: **Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype.** *Hum Genet.* 2016; **135**(12): 1343–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Yavarna T, Al-Dewik N, Al-Mureikhi M, *et al.*: **High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders.** *Hum Genet.* 2015; **134**(9): 967–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
144. Firth HV, Richards SM, Bevan AP, *et al.*: **DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.** *Am J Hum Genet.* 2009; **84**(4): 524–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
145. Smigiel R, Kostrzewa G, Kosinska J, *et al.*: **Further evidence for GRIN2B mutation as the cause of severe epileptic encephalopathy.** *Am J Med Genet A.* 2016; **170**(12): 3265–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
146. Bosch DG, Boonstra FN, de Leeuw N, *et al.*: **Novel genetic causes for cerebral visual impairment.** *Eur J Hum Genet.* 2016; **24**(5): 660–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. Hamdan FF, Srour M, Capo-Chichi JM, *et al.*: **De Novo Mutations in Moderate or Severe Intellectual Disability.** *PLoS Genet.* 2014; **10**(10): e1004772.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Takasaki Y, Koide T, Wang C, *et al.*: **Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese population.** *Sci Rep.* 2016; **6**: 33311.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Morisada N, Ioroi T, Taniguchi-Ikeda M, *et al.*: **A 12p13 GRIN2B deletion is associated with developmental delay and macrocephaly.** *Hum Genome Var.* 2016; **3**: 16029.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
150. Dimassi S, Andrieux J, Labalme A, *et al.*: **Interstitial 12p13.1 deletion involving GRIN2B in three patients with intellectual disability.** *Am J Med Genet A.* 2013; **161A**(10): 2564–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
151. Mishra N, Kouzmitcheva E, Orsino A, *et al.*: **Chromosome 12p Deletion Spanning the GRIN2B Gene Presenting With a Neurodevelopmental Phenotype: A Case Report and Review of Literature.** *Child Neurol Open.* 2016; **3**: 2329048X16629980.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
152. Talkowski ME, Rosenfeld JA, Blumenthal I, *et al.*: **Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries.** *Cell.* 2012; **149**(3): 525–37.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
153. Griswold AJ, Ma D, Cukier HN, *et al.*: **Evaluation of copy number variations reveals novel candidate genes in autism spectrum disorder-associated pathways.** *Hum Mol Genet.* 2012; **21**(15): 3513–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
154. Lal D, Steinbrücker S, Schubert J, *et al.*: **Investigation of GRIN2A in common epilepsy phenotypes.** *Epilepsy Res.* 2015; **115**: 95–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
155. Singh D, Lau M, Ayers T, *et al.*: **De Novo Heterogeneous Mutations in SCN2A and GRIN2A Genes and Seizures With Ictal Vocalizations.** *Clin Pediatr (Phila).* 2016; **55**(9): 867–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
156. Wollmuth LP, Kuner T, Sakmann B: **Adjacent asparagines in the NR2-subunit of the NMDA receptor channel control the voltage-dependent block by extracellular Mg²⁺.** *J Physiol.* 1998; **506**(Pt 1): 13–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
157. Mayer ML: **Glutamate receptors at atomic resolution.** *Nature.* 2006; **440**(7083): 456–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
158. Platzer K, Lemke JR: **GRIN2B-Related Neurodevelopmental Disorder.** In: Adam MP, Ardinger HH, Pagon RA *et al.*: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2019. 2018; May 31.
[PubMed Abstract](#)
159. Andreoli V, de Marco EV, Trecroci F, *et al.*: **Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer’s disease.** *J Neural Transm (Vienna).* 2014; **121**(5): 533–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
160. **F** O’Roak BJ, Vives L, Girirajan S, *et al.*: **Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations.** *Nature.* 2012; **485**(7397): 246–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
161. Soto D, Altafaj X, Sindreu C, *et al.*: **Glutamate receptor mutations in psychiatric and neurodevelopmental disorders.** *Commun Integr Biol.* 2014; **7**(1): e27887.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. Delahanty RJ, Kang JQ, Brune CW, *et al.*: **Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism.** *Mol Psychiatry.* 2011; **16**(1): 86–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
163. Shi YW, Zhang Q, Cai K, *et al.*: **Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes.** *Brain.* 2019; **142**(10): 3028–3044.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Janve VS, Hernandez CC, Verdier KM, *et al.*: **Epileptic encephalopathy de novo GABRB mutations impair γ -aminobutyric acid type A receptor function** *Ann Neurol.* 2016; **79**(5): 806–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
165. Lu W, Constantine-Paton M: **Eye opening rapidly induces synaptic potentiation and refinement.** *Neuron.* 2004; **43**(2): 237–49.
[PubMed Abstract](#) | [Publisher Full Text](#)
166. Kotermanski SE, Johnson JW: **Mg²⁺ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine.** *J Neurosci.* 2009; **29**(9): 2774–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
167. Glasgow NG, Wilcox MR, Johnson JW: **Effects of Mg²⁺ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.** *Neuropharmacology.* 2018; **137**: 344–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
168. Perszyk RE, DiRaddo JO, Strong KL, *et al.*: **GluN2D-Containing N-methyl-D-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.** *Mol Pharmacol.* 2016; **90**(6): 689–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Wen-Jun Gao

Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

2. David A. Lynch

Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research